Download MendeleyThe discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.
Ho, G.D., Yang, S.W., Smotryski, J., Bercovici, A., Nechuta, T., Smith, E.M., McElroy, W., Tan, Z., Tulshian, D., McKittrick, B., Greenlee, W.J., Hruza, A., Xiao, L., Rindgen, D., Mullins, D., Guzzi, M., Zhang, X., Bleickardt, C., Hodgson, R.(2012) Bioorg Med Chem Lett 22: 1019-1022
- PubMed: 22222034
- DOI: https://doi.org/10.1016/j.bmcl.2011.11.127
- Primary Citation of Related Structures:
3UUO - PubMed Abstract:
High-throughput screening identified a series of pyrazoloquinolines as PDE10A inhibitors. The SAR development led to the discovery of compound 27 as a potent, selective, and orally active PDE10A inhibitor. Compound 27 inhibits MK-801 induced hyperactivity at 3mg/kg with an ED(50) of 4mg/kg and displays a ∼6-fold separation between the ED(50) for inhibition of MK-801 induced hyperactivity and hypolocomotion in rats.
Organizational Affiliation:
Department of Medicinal Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA. ginny.ho@merck.com; ginny.ho@spcorp.com
